Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo Nordisk's experimental obesity drug CagriSema delivered 25% average weight loss among adult women in a new analysis run after a late-stage trial, the Danish company said Tuesday. The figure positions the next-generation injection as an improvement on Wegovy, the company's blockbuster GLP-1 obesity shot.

The headline number matters because Novo is framing CagriSema as the successor to Wegovy, not a side product. A 25% mean reduction in a defined subgroup gives the company a concrete efficacy benchmark to point to as it makes the case that CagriSema can outperform its current flagship.

Interpretation: this is a post-hoc analysis of a late-stage trial, restricted to women, so it is a subgroup readout rather than a fresh primary endpoint. Traders should treat the 25% figure as supportive evidence for the thesis, not a replacement for full-population data. The release does add a quantified data point to the competitive narrative around Wegovy's follow-on.

The announcement keeps attention on how much of Novo's future growth rides on moving patients from Wegovy to a stronger-performing successor. Investors will weigh whether subgroup strength translates into the broader trial population and, ultimately, regulatory and commercial outcomes.